Proqr Therapeuti Stock Price, News & Analysis

ProQR Therapeutics (Nasdaq: PRQR), a company focused on RNA therapies using its Axiomer™ RNA editing technology platform, has announced its Annual General Meeting (AGM) of Shareholders. The meeting is scheduled for June 3, 2025, at 15:30 CEST and will be held at Allen Overy Shearman Sterling LLP's offices in Amsterdam, Netherlands.

All meeting-related documents and information will be accessible through ProQR's website under the "Investors & Media" section and on the SEC's website. Shareholders interested in attending must register according to the provided instructions in the notice and agenda.

ProQR Therapeutics (Nasdaq: PRQR) has announced key leadership appointments to support its next growth phase, focusing on its Axiomer™ RNA editing technology platform. Dennis Hom joins as Chief Financial Officer, bringing over 25 years of financial leadership and experience in raising $4.5 billion in capital and executing transactions worth $57 billion. Dr. Cristina Lopez Lopez assumes the role of Chief Medical Officer, contributing 20 years of global leadership in translational R&D.

Hom will oversee corporate development functions, including finance, investor relations, and business development. Dr. Lopez Lopez will lead preclinical, translational, clinical, and regulatory activities. Current CFO Jurriaan Dekkers and Chief Corporate Development Officer René Beukema will step down but remain during the transition period.

ProQR Therapeutics (NASDAQ: PRQR) has reported its financial and operating results for 2024, highlighting significant progress in its RNA editing pipeline. The company ended 2024 with €149.4 million in cash, providing runway into mid-2027.

Key developments include anticipated clinical data readouts for four programs in 2025-2026, led by AX-0810 targeting NTCP for Cholestatic diseases. The company successfully completed an $82.1 million public offering in October 2024 and expanded its collaboration with the Rett Syndrome Research Trust for up to $9.2 million.

Financial highlights show research and development costs increased to €36.4 million in 2024 (vs €25.1 million in 2023), while general and administrative costs decreased to €13.7 million (vs €16.2 million in 2023). Net loss for 2024 was €27.8 million (€0.32 per share), compared to €27.7 million (€0.35 per share) in 2023.

ProQR Therapeutics (NASDAQ: PRQR) announced an expanded collaboration with the Rett Syndrome Research Trust (RSRT), securing an additional $8.1 million in funding, bringing the total to $9.1 million. The funding will support the advancement of AX-2402, a therapeutic candidate based on ProQR's Axiomer RNA editing platform, into clinical trials.

The treatment targets individuals with Rett syndrome who have the R270X mutation in MECP2 gene. Rett Syndrome, affecting approximately 350,000 people worldwide, predominantly girls, is a rare neurodevelopmental disorder with no current cure. The expanded collaboration focuses on optimizing therapeutic candidates targeting the MECP2 protein and advancing them toward clinical development.

ProQR Therapeutics (Nasdaq: PRQR) has appointed Dr. Peter Beal as Chief ADAR Scientist. Dr. Beal, a professor of Chemistry at the University of California, Davis, and a former Scientific Advisory Board member, will oversee platform optimization and scientific developments in RNA editing oligonucleotides design.

As Chief ADAR Scientist, Dr. Beal will leverage his extensive expertise in ADAR biology and RNA chemistry to advance ProQR's Axiomer™ RNA editing technology platform. His research has focused on ADAR-mediated RNA-editing mechanisms, including applications for treating conditions like Rett syndrome, Alzheimer's disease, and Parkinson's disease.

ProQR Therapeutics (Nasdaq: PRQR) announced a virtual Analyst and Investor Event scheduled for December 11, 2024, from 10:00 am to 12:30 pm EST. The event will showcase the company's Axiomer™ ADAR-mediated RNA editing platform and provide updates on development candidates, including NTCP and B4GALT1 programs, AX-0810, and AX-1412.

Key presenters include Daniel A. de Boer (Founder and CEO), Gerard Platenburg (Chief Scientific Officer), and René Beukema (Chief Corporate Development Officer). Guest speakers include Dr. Peter Beal, Professor at UC Davis and expert in ADAR enzymes, and Prof. Gideon Hirschfield, specialist in autoimmune liver diseases from the Toronto Centre for Liver Disease.

The event will be accessible via webcast on ProQR's website, with a phone option available through pre-registration. A replay will be available for approximately 30 days following the event.

ProQR Therapeutics reported Q3 2024 financial results, highlighting €89.4 million in cash and cash equivalents, plus $82.1 million from October financing extending runway into mid-2027. The company's first Axiomer™ RNA editing program, AX-0810, targets NTCP for cholestatic diseases and is advancing toward clinical trials. Q3 net loss was €8.1 million (€0.10 per share), compared to €5.4 million (€0.07 per share) in Q3 2023. R&D costs increased to €9.4 million from €5.4 million year-over-year, while G&A costs remained stable at €3.3 million. The company achieved $5.5 million in milestones from its Eli Lilly collaboration during the first three quarters of 2024.

ProQR Therapeutics announced the closing of its underwritten public offering of 18,000,000 ordinary shares at $3.50 per share, raising gross proceeds of $63.0 million. Additionally, the company completed a concurrent private placement with Eli Lilly and Company for 3,523,538 ordinary shares at the same price, generating approximately $12.3 million in gross proceeds. The combined offerings total $75.3 million in gross proceeds. Evercore ISI, Cantor, Raymond James and Oppenheimer & Co. served as joint lead bookrunning managers for the public offering.

ProQR Therapeutics (Nasdaq: PRQR) has priced an underwritten public offering of 18 million ordinary shares at $3.50 per share, raising gross proceeds of $63.0 million. The company also granted underwriters a 30-day option to purchase up to 2.7 million additional shares. Concurrently, Eli Lilly agreed to purchase 3.52 million shares in a private placement at the same price to maintain its 16.4% ownership stake, contributing additional gross proceeds of $12.3 million. The combined proceeds will fund research, development, and clinical programs, along with working capital and general corporate purposes. The offering is expected to close on October 24, 2024.